tert-butyl ((5-methylpyrrolidin-3-yl)methyl)carbamate | 1374653-91-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl ((5-methylpyrrolidin-3-yl)methyl)carbamate
• 英文别名: tert-butyl N-[(5-methylpyrrolidin-3-yl)methyl]carbamate
• CAS: 1374653-91-4
• 化学式: C₁₁H₂₂N₂O₂
• mdl: MFCD22565933
• 分子量: 214.308
• InChiKey: WKMNQHVVKMVXIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-溴乙氧基)-4-氯苯 、 tert-butyl ((5-methylpyrrolidin-3-yl)methyl)carbamate 在 potassium carbonate 、 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 16.0h， 生成 tert-butyl ((1-(2-(4-chlorophenoxy)ethyl)-5-methylpyrrolidin-3-yl)methyl)carbamate
  参考文献：
  名称：

  [EN] CHEMCICAL COMPOUNDS
  [FR] COMPOSÉS CHIMIQUES

  摘要：

  该发明涉及取代吡咯烷衍生物。具体而言，该发明涉及符合以下式III的化合物：其中A、B、L1、L2、L3、R1、R2、R3、R4、R5、R6、R9、R10、R30、Y1、Y2、z2、z4、z5和z6如本文所定义，并其盐。该发明的化合物是ATF4途径的抑制剂，可用于治疗癌症、癌前综合征以及与激活的未折叠蛋白应答途径相关的疾病，如阿尔茨海默病、脊髓损伤、创伤性脑损伤、缺血性中风、中风、糖尿病、帕金森病、亨廷顿病、克雅氏病、相关朊蛋白病、进行性核上性麻痹、肌萎缩侧索硬化、心肌梗死、心血管疾病、炎症、纤维化、肝脏慢性和急性疾病、肺部慢性和急性疾病、肾脏慢性和急性疾病、慢性创伤性脑病（CTE）、神经退行性疾病、痴呆、认知障碍、动脉粥样硬化、眼部疾病、心律失常、器官移植以及器官移植用途。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制ATF4途径和治疗相关疾病的方法。

  公开号：

  WO2017212423A1

文献信息

• Chemical compounds
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10851053B2

  公开（公告）日：2020-12-01

  The invention is directed to substituted pyrrolidine derivatives. Specifically, the invention is directed to compounds according to Formula III: wherein A, B, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, R10, R30, Y1, Y2, z2, z4, z5, and z6 are as defined herein, and salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代的吡咯烷衍生物。具体地说，本发明针对的是符合式 III 的化合物： 其中 A、B、L1、L2、L3、R1、R2、R3、R4、R5、R6、R9、R10、R30、Y1、Y2、z2、z4、z5 和 z6 如本文所定义，及其盐类。 本发明的化合物是 ATF4 途径的抑制剂，可用于治疗癌症、癌前综合征和与活化的未折叠蛋白反应途径相关的疾病，如阿尔茨海默病、脊髓损伤、创伤性脑损伤、缺血性中风、脑卒中、糖尿病、帕金森病、亨廷顿氏病、克雅氏病和相关的朊病毒病、进行性核上性麻痹、肌萎缩性脊髓侧索硬化症、心肌梗塞、心血管疾病、炎症、纤维化、肝脏慢性和急性疾病、肺部慢性和急性疾病、肾脏慢性和急性疾病、慢性创伤性脑病（CTE）、神经变性、痴呆、认知障碍、动脉粥样硬化、眼部疾病、心律失常、器官移植和器官移植运输。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物抑制 ATF4 通路和治疗与之相关疾病的方法。
• Chemical Compounds
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20190144384A1

  公开（公告）日：2019-05-16

  The invention is directed to substituted pyrrolidine derivatives. Specifically, the invention is directed to compounds according to Formula III: wherein A, B, L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 , R 30 , Y 1 , Y 2 , z 2 , z 4 , z 5 , and z 6 are as defined herein, and salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.